Cytosorbents マネジメント

マネジメント基準チェック /24

Cytosorbentsの CEO はPhil Chanで、 Jan2009年に任命され、の在任期間は 15.83年です。の年間総報酬は$ 1.33Mで、 36.2%給与と63.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.35%を直接所有しており、その価値は$ 680.22K 。経営陣と取締役会の平均在任期間はそれぞれ4.5年と10.2年です。

主要情報

Phil Chan

最高経営責任者

US$1.3m

報酬総額

CEO給与比率	36.2%
CEO在任期間	15.8yrs
CEOの所有権	1.4%
経営陣の平均在職期間	4.5yrs
取締役会の平均在任期間	10.2yrs

経営陣の近況

Recent updates

The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More

Oct 01

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

Jul 04

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Mar 16

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Jan 06

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Nov 10

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Jul 13

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

Sep 09

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Sep 02

CytoSorbents gets reimbursement for CytoSorb in Turkey

Aug 23

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Aug 17

Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M

Aug 02

CEO報酬分析

Cytosorbents の収益と比較して、Phil Chan の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$19m
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$28m
Dec 31 2023	US$1m	US$483k	-US$29m
Sep 30 2023	n/a	n/a	-US$23m
Jun 30 2023	n/a	n/a	-US$26m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$1m	US$483k	-US$33m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$2m	US$483k	-US$25m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$10m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	US$1m	US$456k	-US$8m
Sep 30 2020	n/a	n/a	-US$11m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$1m	US$438k	-US$19m
Sep 30 2019	n/a	n/a	-US$21m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$1m	US$400k	-US$17m
Sep 30 2018	n/a	n/a	-US$15m
Jun 30 2018	n/a	n/a	-US$14m
Mar 31 2018	n/a	n/a	-US$10m
Dec 31 2017	US$828k	US$378k	-US$9m

報酬と市場: Philの総報酬 ($USD 1.33M ) は、 US市場 ($USD 647.72K ) の同規模の企業の平均を上回っています。

報酬と収益: Philの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Phil Chan (54 yo)

15.8yrs

在職期間

US$1,333,402

報酬

Dr. Phillip P. Chan, M.D., Ph D., is known as Phil has been the Chief Executive Officer at Cytosorbents Corporation since January 2009 and served as its President until May 2020. Dr. Chan serves as a Partn...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Phillip Chan	CEO & Director	15.8yrs	US$1.33m	1.35% $ 680.2k
Vincent Capponi	President & COO	19.3yrs	US$1.11m	0.51% $ 258.6k
Kathleen Bloch	Advisor	less than a year	US$816.08k	0.54% $ 271.3k
Efthymios Deliargyris	Chief Medical Officer	4.5yrs	US$1.06m	0.17% $ 86.4k
Peter Mariani	Chief Financial Officer	less than a year	データなし	データなし
Terri Powers	Vice President of Investor Relations & Corporate Communications	3.4yrs	データなし	データなし
Christian Steiner	Executive Vice President of Sales & Marketing	12.4yrs	データなし	データなし
Christopher Cramer	Senior Vice President of Business Development	1.8yrs	データなし	データなし
Jodi Hoover	Executive	no data	データなし	データなし
Robert Bartlett	Co-Chairman of Cardiac Surgery Advisory Board & Consultant	7.4yrs	US$97.32k	データなし

4.5yrs

平均在職期間

63yo

平均年齢

経験豊富な経営陣: CTSOの経営陣は経験豊富であると考えられます ( 4.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Phillip Chan	CEO & Director	16.3yrs	US$1.33m	1.35% $ 680.2k
Robert Bartlett	Co-Chairman of Cardiac Surgery Advisory Board & Consultant	10.2yrs	US$97.32k	データなし
Claudio Ronco	Member of Critical Care Advisory Board	no data	データなし	データなし
Alan Sobel	Independent Director	10yrs	US$118.47k	0.063% $ 31.8k
Edward Jones	Independent Director	17.6yrs	US$101.93k	0.036% $ 18.0k
Joseph Parrillo	Member of Critical Care Advisory Board	no data	データなし	データなし
Ronald Maier	Chairman of the Trauma Advisory Board	11.6yrs	データなし	データなし
Mitchell Cohen	Member of Trauma Advisory Board	no data	データなし	データなし
Ernest Moore	Member of Trauma Advisory Board	11.6yrs	データなし	データなし
Joseph Zwischenberger	Chairman of Cardiac Surgery Advisory Board	10.2yrs	データなし	データなし
Jonathan Haft	Member of Cardiac Surgery Advisory Board	10.2yrs	データなし	データなし
Michael Bator	Independent Chairman of the Board	9.3yrs	US$161.70k	0.10% $ 51.6k

10.2yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: CTSOの取締役会は経験豊富で経験豊富です ( 10.2年の平均在任期間)。

Cytosorbents マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Cytosorbents Corporation Announces Chief Financial Officer Changes

Cytosorbents Corporation, Annual General Meeting, Jun 06, 2024

Cytosorbents Corporation Announces Appointment of Kathleen Bloch as Full-Time CFO

Cytosorbents Corporation Announces Resignation of Alexander D’Amico as Chief Financial Officer, Effective August 28, 2023

CytoSorbents Corporation Appoints Alexander D'Amico as Chief Financial Officer

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

Recent updates

New minor risk - Profitability

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2026

Cytosorbents Corporation Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification

Cytosorbents Corporation to Report Q3, 2024 Results on Nov 07, 2024

The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More

Cytosorbents Corporation Submits Drugsorb-Atr Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor

Consensus EPS estimates upgraded to US$0.31 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cytosorbents Corporation Announces Chief Financial Officer Changes

Cytosorbents Corporation to Report Q2, 2024 Results on Aug 13, 2024

CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

CytoSorbents Corporation Announces Regulatory Approval of CytoSorb® in Taiwan

Cytosorbents Corporation Announces the Launch and Immediate Availability of the PuriFi Blood Pump in the European Union

Cytosorbents Corporation Receives Notice Regarding Nasdaq Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.64 loss per share (vs US$0.75 loss in FY 2022)

No longer forecast to breakeven

Cytosorbents Corporation to Report Q1, 2024 Results on May 09, 2024

Cytosorbents Corporation, Annual General Meeting, Jun 06, 2024

No longer forecast to breakeven

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Cytosorbents Corporation to Report Fiscal Year 2023 Results on Mar 14, 2024

Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial (Rct) Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Price target decreased by 20% to US$4.50

New minor risk - Profitability

Price target decreased by 10.0% to US$5.40

Cytosorbents Corporation Provides Update on the Star-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

New minor risk - Shareholder dilution

Cytosorbents Corporation has completed a Follow-on Equity Offering in the amount of $10.28501 million.

Cytosorbents Corporation announced that it expects to receive $10.28501 million in funding

New minor risk - Share price stability

Consensus EPS estimates fall by 20%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Cytosorbents Corporation Announces Appointment of Kathleen Bloch as Full-Time CFO

Cytosorbents Corporation Announces Resignation of Alexander D’Amico as Chief Financial Officer, Effective August 28, 2023

CytoSorbents Corporation Completes U.S. and Canadian Star-T Pivotal Trial

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cytosorbents Corporation to Report Q2, 2023 Results on Aug 01, 2023

CytoSorbents Corporation Appoints Alexander D'Amico as Chief Financial Officer

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

New minor risk - Share price stability

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Consensus EPS estimates fall by 25%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO & Director exercised options to buy US$97k worth of stock.

Consensus EPS estimates fall by 34%

Full year 2022 earnings released: US$0.75 loss per share (vs US$0.57 loss in FY 2021)

Forecast breakeven date pushed back to 2025

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Cytosorbents Corporation to Report Q4, 2022 Results on Mar 09, 2023

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

Cytosorbents Corporation Appoints Irina B. Kulinets as Senior Vice President of Global Regulatory Affairs

Cytosorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal Star-T Trial as Planned Without Modifications

Consensus EPS estimates fall by 18%

Insufficient new directors

Cytosorbents Announces Pivotal Star-T Trial Reaches First Milestone with 40 Patients Enrolled

Consensus EPS estimates fall by 18%

Consensus EPS estimates fall by 18%

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.15 loss in 3Q 2021)

Price target decreased to US$6.67

CytoSorbents Corporation Announces Presentation of Final Key Results from the U.S. Multicenter Cytosorb Therapy

Cytosorbents Corporation to Report Q3, 2022 Results on Nov 03, 2022

CytoSorbents Corporation Announces Retirement of Kathleen P. Bloch, Chief Financial Officer

マネジメント基準チェック /24